He Jin, Zhu Tianyu, Yu Lin, Mao Ningning, Lu Xuanqi, Shi Xiaofeng, Deng Xiangwen, Yang Yang, Wang Deyun
College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, PR China.
Mater Today Bio. 2025 May 31;32:101939. doi: 10.1016/j.mtbio.2025.101939. eCollection 2025 Jun.
Oral vaccines received great interest in preventing of global pandemics due to the ability to facilitate both systemic and mucosal immune responses. However, the enzymatic degradation, low permeability of mucus barrier, and lack of effective and safe mucosal adjuvants continue to remain significant challenge for oral vaccine. Herein, we developed a novel delivery system based on nanoparticles functionalized by plant polysaccharides to address the above challenges. Firstly, the polysaccharide (CDP) functional-dendritic fibrous nano-silica (DFNS) nanoparticles (CDP-DFNS) were prepared. Encouragingly, the CDP-DFNS with prominent physicochemical and structural characteristics showed high cellular uptake and lead to a high transmembrane transport and intestinal epithelium permeability of antigen. Furthermore, CDP-DFNS significantly induced the antigen internalization and activation of dendritic cells after transport across epithelial cells. In addition, the in vivo experiment results reveled that CDP-DFNS was efficiently facilitated both antigen-specific systemic and mucosal immunity. In conclusion, CDP-DFNS represents a promising candidate for oral vaccine delivery, offering a unique combination of carrier and adjuvant properties. However, further research is needed to evaluate its efficacy in larger animal models and human clinical trials to confirm its translational potential, and fully establish its potential as a next-generation oral vaccine platform.
口服疫苗因能够促进全身和黏膜免疫反应而在预防全球大流行方面备受关注。然而,酶促降解、黏液屏障的低渗透性以及缺乏有效且安全的黏膜佐剂仍然是口服疫苗面临的重大挑战。在此,我们开发了一种基于植物多糖功能化纳米颗粒的新型递送系统,以应对上述挑战。首先,制备了多糖(CDP)功能化树枝状纤维纳米二氧化硅(DFNS)纳米颗粒(CDP-DFNS)。令人鼓舞的是,具有突出物理化学和结构特征的CDP-DFNS显示出高细胞摄取率,并导致抗原具有高跨膜转运和肠上皮通透性。此外,CDP-DFNS在跨上皮细胞转运后显著诱导树突状细胞的抗原内化和活化。另外,体内实验结果表明,CDP-DFNS有效地促进了抗原特异性全身免疫和黏膜免疫。总之,CDP-DFNS是口服疫苗递送的一个有前景的候选者,具有载体和佐剂特性的独特组合。然而,需要进一步研究以评估其在更大动物模型和人体临床试验中的疗效,以确认其转化潜力,并充分确立其作为下一代口服疫苗平台的潜力。